Oncusp Therapeutics Raises Oversubscribed $100 Million Series A Financing To Advance Portfolio Of Assets For Cancer Patients
PRIVATEJan 04, 2024
Amount Raised
$100 Million
Round Type
Series A
New YorkBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Investors
Bio Track CapitalCjnv Bio VentureBlackbird Bio VenturesForge Life Science PartnersMarshall WaceCatalio Capital ManagementSofinnova InvestmentsF Prime CapitalOrbi MedNovo Holdings
Description
OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced an oversubscribed $100 million Series A financing round.
Company Information
Company
OnCusp Therapeutics
Location
New York, New York, United States
About
OnCusp Therapeutics is transforming a growing portfolio of cutting-edge molecules into innovative treatments that deliver help and hope to cancer patients worldwide.
The company is led by a founding team that has deep experience in business development, clinical development and building start-up biopharmaceutical company. OnCusp continually strives to optimize the largest value inflection point in the drug development value chain and believes that accelerating oncology drug innovation is the best way to deliver help and hope to cancer patients worldwide.
Fundz sees it the moment OnCusp Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma